Abstract
The chemokine CXCL12 and its receptor CXCR4 play context-dependent roles in hair follicle biology. While recent findings suggest that regulatory T cells (Tregs) utilize the CXCL12-CXCR4 axis to modestly promote hair follicle regeneration under homeostatic conditions, a substantial body of evidence indicates that this same axis principally drives pathological processes leading to hair loss in alopecia. In androgenetic alopecia (AGA) and alopecia areata (AA) - the most common forms of hair loss - CXCL12-CXCR4 signaling fosters a fibroimmune microenvironment characterized by dermal fibrosis, chronic inflammation, and hair follicle miniaturization. CXCR4 expression in diseased scalp is found predominantly on pro-inflammatory macrophages and dermal papilla cells (DPCs), rather than on Tregs, implicating these cells in propagating hair follicle damage. Correspondingly, elevated CXCL12 from dermal fibroblasts recruits immune effectors and enhances CXCR4 signaling in follicular cells, linking hormonal or autoimmune triggers to hair follicle destruction. Treg-expressed CXCR4 contributes only a minor, context-dependent influence on hair growth, often overwhelmed by the potent pathological signals in alopecia. Therapeutically, inhibiting the CXCL12-CXCR4 axis in both AGA and AA models consistently reverses fibrosis, curtails pathogenic immune cell accumulation, restores DPC function, and stimulates robust hair regrowth. This perspective synthesizes current evidence on: (1) the cellular sources of CXCR4 in alopecic tissue; (2) the pathogenic role of CXCL12-CXCR4 signaling in AGA and AA; (3) the limited scope of Treg CXCR4 function in healthy hair growth; (4) outcomes of CXCL12/CXCR4 blockade as a treatment strategy; and (5) key confounding factors to consider when interpreting CXCR4's role in hair biology.